How to assess pharmacogenomic tests for implementation in the NHS in England

Sonali Sanghvi*, Robin E. Ferner, Andrew Scourfield, Robert Urquhart, Sejal Amin, Aroon D. Hingorani, Reecha Sofat*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    176 Downloads (Pure)

    Abstract

    Aims: Pharmacogenomic testing has the potential to target medicines more effectively towards those who will benefit and avoid use in individuals at risk of harm. Health economies are actively considering how pharmacogenomic tests can be integrated into health care systems to improve use of medicines. However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost‐effectiveness, and operational requirements. We sought to develop a framework that could aid the implementation of pharmacogenomic testing. We take the view from the National Health Service (NHS) in England. Methods: We used a literature review using EMBASE and Medline databases to identify prospective studies of pharmacogenomic testing, focusing on clinical outcomes and implementation of pharmacogenomics. Using this search, we identified key themes relating to the implementation of pharmacogenomic tests. We used a clinical advisory group with expertise in pharmacology, pharmacogenomics, formulary evaluation, and policy implementation to review data from our literature review and the interpretation of these data. With the clinical advisory group, we prioritized themes and developed a framework to evaluate proposals to implement pharmacogenomics tests. Results: Themes that emerged from review of the literature and subsequent discussion were distilled into a 10‐point checklist that is proposed as a tool to aid evidence‐based implementation of pharmacogenomic testing into routine clinical care within the NHS. Conclusion: Our 10‐point checklist outlines a standardized approach that could be used to evaluate proposals to implement pharmacogenomic tests. We propose a national approach, taking the view of the NHS in England. Using this approach could centralize commissioning of appropriate pharmacogenomic tests, reduce inequity and duplication using regional approaches, and provide a robust and evidence‐based framework for adoption. Such an approach could also be applied to other health systems.
    Original languageEnglish
    Number of pages9
    JournalBritish Journal of Clinical Pharmacology
    Early online date14 Jun 2023
    DOIs
    Publication statusE-pub ahead of print - 14 Jun 2023

    Keywords

    • pharmacogenomics
    • health service
    • implementation

    Fingerprint

    Dive into the research topics of 'How to assess pharmacogenomic tests for implementation in the NHS in England'. Together they form a unique fingerprint.

    Cite this